(Q34453555)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182193%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

review article

1 reference

title

Progress in targeting HIV-1 entry (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182193%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182193%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Hugues J-P Ryser

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182193%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

1 August 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182193%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182193%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182193%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182193%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

1085-1094

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182193%20AND%20SRC:MED&resulttype=core&format=json

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

The catalytic activity of protein disulfide isomerase is involved in human immunodeficiency virus envelope-mediated membrane fusion after CD4 cell binding

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Core structure of gp41 from the HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Atomic structure of the ectodomain from HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Structure of an unliganded simian immunodeficiency virus gp120 core

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Functional evolution of the HIV-1 envelope glycoprotein 120 association site of glycoprotein 41.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

The C- and the N-terminal regions of glycoprotein 41 ectodomain fuse membranes enriched and not enriched with cholesterol, respectively

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

The HIV Env-mediated fusion reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Virus entry as a target for anti-HIV intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

The entry of entry inhibitors: a fusion of science and medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

New advances in HIV entry inhibitors development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Prospects of HIV-1 entry inhibitors as novel therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

New approaches toward anti-HIV chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Capture of an early fusion-active conformation of HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Presence of closely spaced protein thiols on the surface of mammalian cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Inter-subunit disulfide bonds in soluble HIV-1 envelope glycoprotein trimers.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903550-6

7 January 2021

10.1016/S1359-6446(05)03550-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182193%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference